Compare SM Energy Company Common Stock (SM) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SM Energy Company Common Stock vs Tango Therapeutics Inc. — how do they compare? SM Energy Company Common Stock trades at $38.5 (market cap $9.09B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: SM Energy Company Common Stock is far larger — about 2.4× Tango Therapeutics Inc.'s market cap, and SM Energy Company Common Stock pays a 2.3% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold SM Energy Company Common Stock for 2 Days and Tango Therapeutics Inc. for 0 Days on average.
| SM | TNGX | |
|---|---|---|
Market Cap | $9.09B | $3.74B |
Volume | 2,055,494 | 3,438,781 |
Sector | Energy | Health |
52-Week High | $41.29 | $32.90 |
52-Week Low | $17.57 | $7.50 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $15.51B | $2.76B |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SM Energy (SM) trades at $38.54, up 2.26% with strong bullish technical signals and consistent earnings beats. The stock shows robust fundamentals with a low P/E of 6.83, healthy profit margins above 19%, and positive cash flow generation. Recent analyst coverage remains overwhelmingly positive with 65% buy ratings and a $39.08 consensus target, slightly above current levels.
Outlook remains favorable given strong earnings momentum and attractive valuation metrics, though overbought RSI readings suggest near-term consolidation risk. The company's upcoming Q3 2026 earnings report on November 3rd represents the next key catalyst for price movement.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SM Energy Company Common Stock
SM Energy is an independent oil and natural gas exploration and production company. Its operations include the Permian, Maverick, Uinta, and Denver-Julesburg basins.
Read more on SM →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
